The results of the trial were so successful that the researchers reached the conclusion that CBD could have the potential to revolutionise treatments for patients suffering from schizophrenia:
“These findings suggest that CBD has beneficial effects in patients with schizophrenia.
“As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”
Speaking to Herb, lead researcher Dr. Philip McGuire, Professor of Psychiatry & Cognitive Neuroscience at King’s College London, explained that it’s possible that cannabidiol could replace current antipsychotic medications for some patients.
“At present, because CBD is a relatively new drug, clinicians might be cautious about using it instead of a well-established treatment like antipsychotic medication.
“This was one reason why we started by assessing it as an adjunctive or add-on to conventional treatment.
“However, if trials of CBD as a monotherapy are positive it would be reasonable to consider using it alone, particularly in patients in whom antipsychotic medication hadn’t worked.”